ABVC BioPharma (NASDAQ:ABVC) Shares Down 7.6% – Should You Sell?

ABVC BioPharma, Inc. (NASDAQ:ABVC) shares dropped 7.6% during trading on Friday . The company traded as low as $1.29 and last traded at $1.33. Approximately 180,196 shares traded hands during trading, an increase of 52% from the average daily volume of 118,251 shares. The stock had previously closed at $1.44.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of ABVC BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, ABVC BioPharma presently has a consensus rating of “Sell”.

ABVC BioPharma Stock Down 7.6%

The stock has a market cap of $34.58 million, a price-to-earnings ratio of -3.32 and a beta of 0.56. The company’s 50-day moving average is $1.19 and its 200-day moving average is $1.69.

ABVC BioPharma (NASDAQ:ABVC) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ABVC. Geode Capital Management LLC raised its position in ABVC BioPharma by 5.8% in the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after purchasing an additional 6,017 shares in the last quarter. Citadel Advisors LLC acquired a new position in ABVC BioPharma in the third quarter worth about $48,000. Finally, Millennium Management LLC acquired a new position in ABVC BioPharma in the third quarter worth about $60,000. Institutional investors and hedge funds own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.